Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
GC Biopharma Corp (006280 KS)
Watchlist
115
Analysis
Health Care
•
South Korea
GC Biopharma is a biopharmaceutical company headquartered in Yongin, South Korea. It manufactures household medical drugs. The Company's product includes medicines for cold and fever, nutrition, antiseptic drug, and a lip balm.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Yuhan Corp
•
21 Dec 2016 15:45
20 Million Chickens (And Ducks) Culled in Korea
It is estimated that more than 20 million chickens (and ducks) have been culled in Korea in the past several weeks, representing about 12% of all...
Douglas Kim
Follow
731 Views
Share
bullish
•
SillaJen Inc
•
29 Nov 2016 05:36
SillaJen IPO Part 5 -Â Revenue & Valuation Estimates with Pexa-Vec's First Commercialization Year
We need to examine the size of SillaJen's expected sales in 2020, which is the reference year for its entire valuation. With an assumption that...
Sanghyun Park
Follow
498 Views
Share
bullish
•
SillaJen Inc
•
26 Nov 2016 03:48
SillaJen IPO Part 4 - IPO Price & Post-IPO Risks
SillaJen IPO price was set at ₩15,000, the lowest end of the indicative price band, after conducting the demand survey from (Nov 23-24) the...
Sanghyun Park
Follow
460 Views
Share
bullish
•
SillaJen Inc
•
21 Nov 2016 13:33
SillaJen IPO Part 3 - Competitive Strengths of Product (Pexa-Vec)
*Â In Part 3 (as below), I summarized the competitive strengths of product (Pexa-Vec).SillaJen's Pexa-Vec is an advanced liver cancer treatment...
Sanghyun Park
Follow
390 Views
Share
bullish
•
SillaJen Inc
•
03 Nov 2016 11:26
SillaJen IPO Part 2 - Growth Potential & Appropriate Valuation Level
* In Part 2 (as below), I summarized the growth potential and appropriate valuation level of SillaJen.Apparently, not many people are doubtful...
Sanghyun Park
Follow
406 Views
Share
First
Previous
13
14
15
16
17
18
19
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.5
x